Vaccines have saved millions of lives. Currently, and for infectious diseases in humans at least, sanitation and vaccination remains the most efficient and the most cost-effective prophylactic treatment available. Vaccination has led to the global eradiation of smallpox, the virtual eradication of polio and a reduction of over 95 % in the incidence of diphtheria, tetanus, This can include difficulty in cultivating the pathogen in vitro, as in the case with Hepatitis B virus (HBV) and parasites such as malaria and schistosoma. Determining that cultured pathogens are killed or sufficiently attenuated for safe inoculation is also of major concern.
plus newly emergent diseases, such as West Nile fever or ebola. Vaccination is also increasingly recognised as an important strategy for food security, by providing protection to livestock against existing and emerging pathogens.
In developing vaccines, there is a range of options for consideration: 1) attenuated vaccines, where the infection is live but weakened e.g. BCG; 2) killed or in-activated vaccines, these are typically prepared by heat or chemical treatment and examples include influenza vaccines; 3) sub-unit or toxoid protein-based vaccines, e.g. HBV and 4) vaccines based on extended carbohydrate epitopes. These traditional approaches have proved successful, clearly evident by the reduction in mortality rates caused by of a number of infectious diseases. However, there can be numerous hurdles to consider in the selection of the vaccine platform design.
This can include difficulty in cultivating the pathogen in vitro, as in the case with Hepatitis B virus (HBV) and parasites such as malaria and schistosoma. Determining that cultured pathogens are killed or sufficiently attenuated for safe inoculation is also of major concern.
However, recombinant DNA technology has enabled the development of protein-based vaccines that can address these particular issues. Indeed, a recombinant protein of the HBV 2 surface antigen, expressed by DNA-transfected cells, has led to a human vaccine against the virus. Other recombinant protein vaccines are being developed and tested including those for tuberculosis, herpes simplex virus (HSV-1), the influenza virus as well as cancers.
In recent times, prompted by several safety concerns, there has been a move away from whole-pathogen vaccines towards sub-unit and epitope ensemble vaccines. Sub-unit vaccines cannot revert to a virulent form; this is a phenomenon apparent amongst certain attenuated vaccines and can prompt a wide range of adverse effects, from severe morbidity to mortality.
This can be supported further by the recent increase in knowledge and expertise in the field of biotechnology which opens up the ability to design new vaccines using synthetic peptides and proteins. Whilst these systems offer enhanced safety profiles compared to live attenuated systems, sub-unit vaccines tend to offer reduced potency. To address this issue adjuvant systems can be exploited.
To stimulate new collaborations and developments in vaccines, the British Council recently Proteomic applications are providing new insights into vaccine development [2] . The review by Dunston et al explores how this technology can be exploited to (a) identify novel exofacial antigens, (b) provide detailed information on the molecular nature of any sub-unit vaccine and (c) provide insight into the host response to vaccination [2] . In another powerful application of proteomics, the paper by Munday et al explores how the syncytial viral infection of epithelial cells alters expression of mitochondrial proteins in a temporal manner [3] . While Tom was found to be protective, hsp90 supported epithelial cell infection by virus [3] . Such knowledge offers novel targets to explore in the development of anti-infective strategies.
Within this issue, we also explore the options available for the production of sub-unit vaccines using yeast. Yeast offers improved yield properties and the ability to synthesise more challenging antigens that we have struggled to produce in other systems [4] . Indeed Nguyen et al., demonstrate that P. pastoris yeast can express and secrete biofunctional fusion proteins [5] . Cuccui and Wren [6] have reviewed how glycosylation or the modification of a cellular component with a carbohydrate moiety e.g. bacterial N-linked protein glycosylation can be exploited for glycobiotechnological applications including glycoconjugate vaccine and humanised glycoprotein production. The authors note that these conjugates may reduce the cost of vaccines thus offering further potential for glycoconjugate vaccines tailored specifically for animal vaccination [6] . McNair also highlights the need for improved animal health through vaccination [7] ; drug resistance is prevalent in many ectoparasites (in human and domestic livestock) and new vaccines against such ectoparasites are urgently required.
Similarly vaccines are required to protect animals against Mycoplasma mycoides-induced mastitis, pneumonia, arthritis, keratitis, as well as acute cases of septicaemia. In a review by Churchwood et al, six proteins were found to have less than 95% amino acid similarity to a closely related Mycoplasma species, thus demonstrating that they merit further investigation and evaluation in the development of diagnostic tests [8] . The challenge in developing effective canine infectious respiratory disease (CIRD) vaccines is also considered [9] ; since CIRD is a complex syndrome involving a multifactorial etiology (including bacterial and viral pathogens) diagnosis and early treatment can be difficult and thus can affect the reduction in [10] . When considering the enhancement of these vaccines through delivery and adjuvants, Walters et al., [11] outline the potential for developing new delivery platforms that would provide singleshot vaccines (using encapsulation in biocompatible polymers) whilst Donnelly et al., [12] 4 have looked at applying dissolving micro-needles as a delivery platform for vaccines. To boost adjuvanticity, Maughan et al., [13] have outlined new developments in the use of particulate inorganic adjuvants and Kastner et al., [14] have looked at the development of liposomal adjuvants using multivariate analysis.
To consider new methods for testing vaccines, Marshall et al., [15] have designed and characterised a multi-cellular model of human airways that takes into account the conditions in the airways and recapitulates many salient features, including the epithelial barrier and mucus secretion. This simulates the barriers to pulmonary delivery of particles and therefore represents a valid test platform for screening vaccines delivered via the pulmonary route.
In summary, whilst there are notable success stories in the development of vaccines, key challenges remain. To address these and develop the next generation of vaccines it is vital for us to exploit the full power of modern biotechnology and computer science as key tools for discovering new and commercially important immunogenic antigens. These must be combined with safe and effective adjuvants and delivery mechanisms to ensure that we can develop cost-effective vaccines that are globally accessible.
